TOP MCC950 SIDE EFFECTS SECRETS

expression, which can be a key driver of NIH. Within an in vivo mouse model of NIH in vascular grafts, MCC950 significantly Improved re‐endothelialization and decreased NIH as compared to PTX or SMS.MCC950, a little-molecule inhibitor, offers a promising alternate by selectively blocking NLRP3 though preserving other inflammasomes such as NLRC4